全文获取类型
收费全文 | 280篇 |
免费 | 27篇 |
国内免费 | 13篇 |
学科分类
医药卫生 | 320篇 |
出版年
2023年 | 3篇 |
2022年 | 3篇 |
2021年 | 10篇 |
2020年 | 10篇 |
2019年 | 19篇 |
2018年 | 15篇 |
2017年 | 9篇 |
2016年 | 19篇 |
2015年 | 9篇 |
2014年 | 12篇 |
2013年 | 5篇 |
2012年 | 14篇 |
2011年 | 9篇 |
2010年 | 5篇 |
2009年 | 3篇 |
2008年 | 9篇 |
2007年 | 9篇 |
2006年 | 9篇 |
2005年 | 15篇 |
2004年 | 10篇 |
2003年 | 11篇 |
2002年 | 8篇 |
2001年 | 12篇 |
2000年 | 4篇 |
1999年 | 6篇 |
1998年 | 3篇 |
1997年 | 3篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1994年 | 2篇 |
1993年 | 4篇 |
1992年 | 13篇 |
1991年 | 7篇 |
1990年 | 8篇 |
1989年 | 11篇 |
1988年 | 4篇 |
1987年 | 2篇 |
1986年 | 1篇 |
1983年 | 1篇 |
1982年 | 3篇 |
1980年 | 2篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 5篇 |
1974年 | 1篇 |
1967年 | 1篇 |
1966年 | 2篇 |
1965年 | 1篇 |
排序方式: 共有320条查询结果,搜索用时 15 毫秒
311.
Linda Sommese Rossella Paolillo Francesco Cacciatore Vincenzo Grimaldi Chiara Sabia Antonella Esposito Antonio Sorriento Carmela Iannone Nicolò Rupealta Gerardo Sarno Michele Santangelo Paride De Rosa Gianfranco Nicoletti Claudio Napoli 《Advances in medical sciences》2018,63(2):317-322
Purpose
Human leukocyte antigen (HLA)-G is a non-classic major histocompatibility complex HLA class I molecule. HLA-G may have tolerogenic properties which are linked to epigenetic-sensitive pathways. There is a correlation of sHLA-G levels and graft acceptance in transplantation studies. There are previous data on correlation of sHLA-G with graft rejection as well as with viral infections such as hepatitis C virus (HCV) in kidney transplanted patients. Here, we report the sHLA-G expression in patients on the waiting list for kidney transplantation, with and without anti-HCV compared to a control group.Methods
Serum of 67 patients on the waiting list for kidney transplantation (n?=?43 with anti-HCV and n?=?24 without anti-HCV) was analyzed. Among these patients, n?=?39 were on the waiting list for the first transplantation, while n?=?28 were patients who returned in the list. The control group included n?=?23 blood donors with anti-HCV (n?=?13) and without anti-HCV (n?=?10).Results
The expression of sHLA-G was significantly lower in the control group (39.6?±?34.1 U/ml) compared to both - patients on the waiting list for the first transplantation (62.5?±?42.4 U/ml, p=0.031) and patients who returned in the list (76.7?±?53.9 U/ml, p=0.006). No significant differences were observed in all anti-HCV positive groups. A positive linear correlation between sHLA-G and TNF-α, and patient age was observed.Conclusions
Serum sHLA-G values were significantly increased in both - patients on the waiting list for the first transplantation and patients who returned in the list, as compared to control group. Our findings confirm the key tolerogenic role of sHLA-G levels as epigenetic-related marker for measuring the state of kidney allograft acceptance. 相似文献312.
Milena Di Leo rea Iannone Monica Arena Giuseppe Losurdo Maria Angela Palamara Giuseppe Iabichino Pierluigi Consolo Maria Rendina Carmelo Luigiano Alfredo Di Leo 《World journal of gastroenterology : WJG》2021,27(45):7748-7770
The incidence of colorectal cancer (CRC) is characterized by rapid declines in the wake of widespread screening. Colonoscopy is the gold standard for CRC screening, but its accuracy is related to high quality of bowel preparation (BP). In this review, we aimed to summarized the current strategy to increase bowel cleansing before colonoscopy. Newly bowel cleansing agents were developed with the same efficacy of previous agent but requiring less amount of liquid to improve patients’ acceptability. The role of the diet before colonoscopy was also changed, as well the contribution of educational intervention and the use of adjunctive drugs to improve patients’ tolerance and/or quality of BP. The review also described BP in special situations, as lower gastrointestinal bleeding, elderly people, patients with chronic kidney disease, patients with inflammatory bowel disease, patients with congestive heart failure, inpatient, patient with previous bowel resection, pregnant/lactating patients. The review underlined the quality of BP should be described using a validate scale in colonoscopy report and it explored the available scales. Finally, the review explored the possible contribution of bowel cleansing in post-colonoscopy syndrome that can be related by a transient alteration of gut microbiota. Moreover, the study underlined several points needed to further investigations. 相似文献
313.
Stopeck AT Unger JM Rimsza LM Leblanc M Farnsworth B Iannone M Glenn MJ Fisher RI Miller TP 《Blood》2012,120(6):1210-1217
S0515 was a phase 2 trial to determine whether the addition of bevacizumab to cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) plus rituximab (R-CHOP) would improve progression-free survival (PFS) without adding significant toxicity in patients with newly diagnosed advanced diffuse large B-cell lymphoma. A total of 73 patients were enrolled. For the 64 eligible patients, median age was 68 years, and 60% had International Prognostic Index scores more than or equal to 3. The observed 1- and 2-year PFS estimates were 77% and 69%, respectively. These PFS estimates were not statistically different from the expected PFS for this population if treated with R-CHOP alone. Grade 3 or higher toxicities were observed in 81% of patients, including 2 grade 5 events. The majority of serious toxicities were hematologic but also included 5 patients with gastrointestinal perforations, 4 patients with thrombotic events, and 11 patients who developed grade 2 or 3 left ventricular dysfunction. Higher baseline urine VEGF and plasma VCAM levels correlated with worse PFS and overall survival. In conclusion, the addition of bevacizumab to R-CHOP chemotherapy was not promising in terms of PFS and resulted in increased serious toxicities, especially cardiac and gastrointestinal perforations. This study is registered at www.clinicaltrials.gov as #NCT00121199. 相似文献
314.
315.
Fabiani Claudia Vitale Antonio Emmi Giacomo Bitossi Alice Lopalco Giuseppe Sota Jurgen Guerriero Silvana Orlando Ida Capozzoli Marco Fusco Fiorella Rana Francesco Iannone Florenzo Frediani Bruno Galeazzi Mauro Vannozzi Lorenzo Tosi Gian Marco Cantarini Luca 《Clinical rheumatology》2019,38(1):63-70
Clinical Rheumatology - The aim of the present study was to compare long-term adalimumab (ADA) and infliximab (IFX) retention rates in patients with intermediate, posterior, or panuveitis.... 相似文献
316.
317.
Iannone F Trotta F Montecucco C Monteccuco C Giacomelli R Galeazzi M Matucci-Cerinic M Ferri C Cutolo M Maria Bambara L Triolo G Ferraccioli G Valentini G Lapadula G;GISEA 《Annals of the rheumatic diseases》2007,66(2):249-252
OBJECTIVE: To evaluate the efficacy of switching to etanercept treatment in patients with rheumatoid arthritis who already responded to infliximab, but presented side effects. METHODS: Charts of 553 patients with rheumatoid arthritis were retrospectively reviewed to select patients who responded to the treatment with infliximab and switched to etanercept because of occurrence of adverse effects. Clinical data were gathered during 24 weeks of etanercept treatment and for the same period of infliximab treatment before infliximab was stopped. Disease Activity Score computed on 44 joints (DAS-44), erythrocyte sedimentation rate (ESR) 1st hour, Visual Analogue Scale (VAS) of pain, Health Assessment Questionnaire (HAQ), and C reactive protein (CRP) were assessed every 8 weeks. RESULTS: 37 patients were analysed. Adverse events to infliximab were mostly infusion reactions. No statistically significant difference between infliximab, before withdrawal, and etanercept, after 24 weeks, was detected in terms of DAS-44 (2.7 and 1.9, respectively), HAQ (0.75 and 0.75, respectively), ESR (21 and 14, respectively) and CRP (0.5 and 0.3, respectively). VAS pain decreased significantly after switching to etanercept treatment (40 and 24, respectively; p<0.05). CONCLUSIONS: Our study shows that etanercept maintains the clinical benefit achieved by infliximab, and suggests that a second tumour necrosis factor (TNF) alpha inhibitor can be the favourable treatment for rheumatoid arthritis when the first TNFalpha blocker has been withdrawn because of adverse events. 相似文献
318.
Esposito G De Falco F Tinto N Testa F Vitagliano L Tandurella IC Iannone L Rossi S Rinaldi E Simonelli F Zagari A Salvatore F 《Human mutation》2011,32(12):1460-1469
Choroideremia (CHM), an X-linked degeneration of the retinal pigmented epithelium (RPE), photoreceptors, and choroid, ultimately leads to blindness. It is caused by loss-of-function of the CHM gene product, the Rab escort protein 1 (REP1) that is involved, together with its homologue REP2, in prenylation of Rab GTPases, key regulators of intracellular vesicular traffic. Here, we report the molecular characterization of 20 unrelated Italian families affected by CHM. We identified 19 different mutations, nine of which are new. In most cases, we analyzed the effect of the mutations at the mRNA level. Furthermore, we demonstrated, by in vitro trancription/translation assays, that the mutated mRNAs produced truncated proteins in all cases but one. In fact, we also identified a novel REP1 missense variant (c.1520A>G; p.H507R) associated to CHM. Thus far, only two other CHM-associated missense mutations have been identified, one of which was a splicing alteration. We investigated the impact of the p.H507R amino acid change on REP1 structure and function, thus providing the first experimental demonstration that correlates a missense mutation in CHM with a functional impairment of REP1. Overall, our results indicate that the REP1-Rab geranyl-geranyl transferase interaction and consequently REP1-mediated Rab prenylation is essential for RPE and photoreceptor function. 相似文献
319.
Massimiliano Fedele Alessandro Iannone Davide Bartolini Paolo Rubartelli 《Clinical Case Reports》2021,9(10)
Under‐expanded coronary stent related to inadequate preparation of calcified lesion is associated with poor clinical outcomes.Off‐label use of S‐IVL to correct this clinical issue is effective and safe, probably more than other current techniques. However, this statement needs further evidence. 相似文献
320.
Michael P. Sherman Rajnikant M. Amin Pamela E. B. Rodgers-Johnson Owen S. C. Morgan Gurendra Char Carlos A. Mora Robert Iannone George H. Collins Lawrence Papsidero Clarence J. Gibbs Bernard J. Poiesz 《Arthritis \u0026amp; Rheumatology》1995,38(5):690-698
Objective. To investigate a possible association between human T cell leukemia/lymphoma virus type I (HTLV-I) and polymyositis (PM). Methods. Sera and muscle biopsy samples from 9 Jamaican PM patients were compared with specimens from American HTLV-I–positive PM patients and normal controls. Sera were evaluated for HTLV antibodies by enzyme-linked immunosorbent assay and Western blot. The biopsy samples were analyzed for HTLV-I/II DNA by polymerase chain reaction and were also immunohistochemically stained for HTLV gp46 envelope protein. Results. Seven of the 8 Jamaican PM patients from whom sera were available were HTLV-I seropositive. The muscle biopsies of all 9 Jamaican patients demonstrated severe lymphocytic infiltration, cellular degeneration, myofiber atrophy, and fibrosis. Each muscle biopsy specimen contained HTLV-I DNA. Two of 6 samples demonstrated intense staining for HTLV-I gp46 in many of the invading mononuclear cells and weak staining for HTLV-I gp46 in many of the invading mononuclear cells and weak staining in the adjacent myocytes. Two other specimens were weakly positive for gp46 in rare mononuclear cells. All control specimens were negative for the presence of HTLV-I DNA and protein. Conclusion. HTLV-I is associated with an inflammatory muscle disease characterized by direct invasion of the affected muscle by HTLV-I–infected mononuclear cells. 相似文献